Literature DB >> 12707575

Upcoming biologic agents for the treatment of rheumatic diseases.

Joseph C Shanahan1, Larry W Moreland, Robert H Carter.   

Abstract

The development of biologic agents has provided rheumatologists with a variety of new and effective treatment options. The success of early biologics, especially etanercept and infliximab for the treatment of rheumatoid arthritis, has spurred research into novel targets for the management of systemic inflammatory and autoimmune diseases. In addition, existing biologics approved for use in other diseases, such as rituximab, are now under study for the treatment of new indications. This article reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12707575     DOI： 10.1097/00002281-200305000-00009

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN： 1040-8711            Impact factor:   5.006


  13 in total

Review 1.  B cells: new ways to inhibit their function in rheumatoid arthritis.

Authors:  Robert H Carter
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 2.  B cell signalling as therapeutic target.

Authors:  R H Carter
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

3.  Protective effects of indomethacin and cyclophosphamide but not of infliximab on liver metabolic changes caused by adjuvant-induced arthritis.

Authors:  Maria Angélica Raffaini Covas Pereira da Silva; Ciomar Aparecida Bersani-Amado; Emy Luiza Ishii-Iwamoto; Lívia Bracht; Silvana Martins Caparroz-Assef
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

4.  Improvement of bioavailability and anti-inflammatory potential of curcumin in combination with emu oil.

Authors:  Manish Kumar Jeengar; Shweta Shrivastava; Kala Nair; Sreenivasa Reddy Singareddy; Uday Kumar Putcha; M V N Kumar Talluri; V G M Naidu; Ramakrishna Sistla
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

5.  Anti-inflammatory and anti-oxidant properties of Curcuma longa (turmeric) versus Zingiber officinale (ginger) rhizomes in rat adjuvant-induced arthritis.

Authors:  Gamal Ramadan; Mohammed Ali Al-Kahtani; Wael Mohamed El-Sayed
Journal:  Inflammation       Date:  2011-08       Impact factor: 4.092

Review 6.  Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.

Authors:  Lili Magyari; Dalma Varszegi; Erzsebet Kovesdi; Patricia Sarlos; Bernadett Farago; Andras Javorhazy; Katalin Sumegi; Zsolt Banfai; Bela Melegh
Journal:  World J Orthop       Date:  2014-09-18

7.  High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study.

Authors:  Stephen A Wright; Emilio Filippucci; Claire McVeigh; Arthur Grey; Maura McCarron; Walter Grassi; Gary D Wright; Allister J Taggart
Journal:  Ann Rheum Dis       Date:  2006-12-21       Impact factor: 19.103

8.  Pharmacological evaluation of anti-arthritic potential of terpinen-4-ol using in vitro and in vivo assays.

Authors:  Sania Aslam; Waqas Younis; Muhammad Nasir Hayat Malik; Shah Jahan; Ambreen Malik Uttra; Muhammad Usman Munir; Muhammad Roman
Journal:  Inflammopharmacology       Date:  2022-03-23       Impact factor: 4.473

9.  A new arthritis therapy with oxidative burst inducers.

Authors:  Malin Hultqvist; Peter Olofsson; Kyra A Gelderman; Jens Holmberg; Rikard Holmdahl
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

10.  Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure.

Authors:  Luis Arturo Gutierrez-Gonzalez; Marco Antonio Rivera Gudiño; Ibell Oropeza Ceija; Marialina Marin Leonet; Zair Tovar Noguera
Journal:  Open Rheumatol J       Date:  2013-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.